AR132544A2 - ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS - Google Patents
ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOSInfo
- Publication number
- AR132544A2 AR132544A2 ARP240101072A ARP240101072A AR132544A2 AR 132544 A2 AR132544 A2 AR 132544A2 AR P240101072 A ARP240101072 A AR P240101072A AR P240101072 A ARP240101072 A AR P240101072A AR 132544 A2 AR132544 A2 AR 132544A2
- Authority
- AR
- Argentina
- Prior art keywords
- n3pglu
- antibodies
- clinical
- peptide antibodies
- n3pglu amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos para Ab N3pGlu humano, composiciones que comprende tales anticuerpos Ab N3pGlu, y métodos para usar tales anticuerpos Ab N3pGlu para el tratamiento de una enfermedad caracterizada por deposición de Ab que incluye Enfermedad de Alzheimer clínica o pre-clínica, Síndrome de Down, y angiopatía amiloide cerebral clínica o pre-clínica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662279268P | 2016-01-15 | 2016-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132544A2 true AR132544A2 (es) | 2025-07-16 |
Family
ID=57966094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100014A AR107290A1 (es) | 2016-01-15 | 2017-01-04 | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
| ARP240101072A AR132544A2 (es) | 2016-01-15 | 2024-04-26 | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100014A AR107290A1 (es) | 2016-01-15 | 2017-01-04 | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9944696B2 (es) |
| EP (1) | EP3402817B1 (es) |
| JP (1) | JP6634158B2 (es) |
| KR (1) | KR102141969B1 (es) |
| CN (2) | CN114891100B (es) |
| AR (2) | AR107290A1 (es) |
| AU (1) | AU2017207250B2 (es) |
| CA (1) | CA3007000C (es) |
| EA (1) | EA037784B1 (es) |
| ES (1) | ES2968255T3 (es) |
| IL (1) | IL259748B2 (es) |
| JO (1) | JOP20170004B1 (es) |
| MX (1) | MX394462B (es) |
| TW (1) | TWI634126B (es) |
| WO (1) | WO2017123517A1 (es) |
| ZA (2) | ZA201803396B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CA3033077C (en) | 2016-08-12 | 2024-06-18 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| JP7514533B2 (ja) | 2018-02-07 | 2024-07-11 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| JP7490239B2 (ja) | 2018-02-07 | 2024-05-27 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化ペメトレキセドおよびその使用 |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| WO2019157125A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated methotrexate and uses thereof |
| CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| EP3752155A4 (en) | 2018-02-14 | 2022-03-16 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF |
| CN111971047A (zh) | 2018-02-14 | 2020-11-20 | L.E.A.F.控股集团公司 | γ聚谷氨酸化四氢叶酸及其用途 |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2020193644A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| US12435129B2 (en) | 2020-07-23 | 2025-10-07 | Othair Prothena Limited | Anti-Aβ antibodies |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CA3236547A1 (en) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Compounds and methods targeting interleukin-34 |
| WO2023076971A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| AR127484A1 (es) | 2021-10-29 | 2024-01-31 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
| CN118475609A (zh) | 2021-10-29 | 2024-08-09 | 伊莱利利公司 | 靶向白细胞介素-34的化合物和方法 |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| CN120731223A (zh) | 2022-12-22 | 2025-09-30 | 生物极公司 | 与AβpE3结合的抗体 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
| CN118459583B (zh) * | 2024-07-11 | 2024-09-10 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1911765A3 (en) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
| EP3338795A1 (en) | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| LT3339323T (lt) * | 2010-08-12 | 2020-02-10 | Eli Lilly And Company | Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas |
| AU2014233615B2 (en) * | 2010-08-12 | 2016-08-11 | Eli Lilly And Company | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
-
2017
- 2017-01-03 JO JOP/2017/0004A patent/JOP20170004B1/ar active
- 2017-01-04 TW TW106100110A patent/TWI634126B/zh active
- 2017-01-04 AR ARP170100014A patent/AR107290A1/es active IP Right Grant
- 2017-01-10 KR KR1020187019854A patent/KR102141969B1/ko active Active
- 2017-01-10 JP JP2018529131A patent/JP6634158B2/ja active Active
- 2017-01-10 IL IL259748A patent/IL259748B2/en unknown
- 2017-01-10 CA CA3007000A patent/CA3007000C/en active Active
- 2017-01-10 ES ES17703491T patent/ES2968255T3/es active Active
- 2017-01-10 MX MX2018008557A patent/MX394462B/es unknown
- 2017-01-10 WO PCT/US2017/012795 patent/WO2017123517A1/en not_active Ceased
- 2017-01-10 EP EP17703491.5A patent/EP3402817B1/en active Active
- 2017-01-10 EA EA201891286A patent/EA037784B1/ru unknown
- 2017-01-10 CN CN202210627760.XA patent/CN114891100B/zh active Active
- 2017-01-10 CN CN201780006700.3A patent/CN108473566B/zh active Active
- 2017-01-10 US US15/402,268 patent/US9944696B2/en active Active
- 2017-01-10 AU AU2017207250A patent/AU2017207250B2/en active Active
-
2018
- 2018-05-22 ZA ZA2018/03396A patent/ZA201803396B/en unknown
-
2019
- 2019-02-26 ZA ZA2019/01207A patent/ZA201901207B/en unknown
-
2024
- 2024-04-26 AR ARP240101072A patent/AR132544A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20170004B1 (ar) | 2022-09-15 |
| CN114891100A (zh) | 2022-08-12 |
| EP3402817A1 (en) | 2018-11-21 |
| CA3007000C (en) | 2021-07-27 |
| KR20180086268A (ko) | 2018-07-30 |
| EP3402817B1 (en) | 2023-10-18 |
| JP6634158B2 (ja) | 2020-01-22 |
| KR102141969B1 (ko) | 2020-08-06 |
| CA3007000A1 (en) | 2017-07-20 |
| EA201891286A1 (ru) | 2018-12-28 |
| WO2017123517A1 (en) | 2017-07-20 |
| TW201739761A (zh) | 2017-11-16 |
| IL259748A (en) | 2018-07-31 |
| US20170204171A1 (en) | 2017-07-20 |
| MX2018008557A (es) | 2018-09-18 |
| IL259748B2 (en) | 2023-03-01 |
| IL259748B (en) | 2022-11-01 |
| AU2017207250A1 (en) | 2018-06-07 |
| CN114891100B (zh) | 2024-05-03 |
| ZA201901207B (en) | 2022-05-25 |
| US9944696B2 (en) | 2018-04-17 |
| BR112018011308A2 (pt) | 2018-11-27 |
| CN108473566B (zh) | 2022-06-17 |
| ZA201803396B (en) | 2025-08-27 |
| TWI634126B (zh) | 2018-09-01 |
| MX394462B (es) | 2025-03-11 |
| AU2017207250B2 (en) | 2019-04-18 |
| AR107290A1 (es) | 2018-04-18 |
| CN108473566A (zh) | 2018-08-31 |
| EA037784B1 (ru) | 2021-05-20 |
| ES2968255T3 (es) | 2024-05-08 |
| JP2019507107A (ja) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| ECSP19075146A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CL2024000824A1 (es) | Composiciones y métodos de inhibición del masp-3 para tratar enfermedades y trastornos div 201900230 | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| MX374012B (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. | |
| EP3334414A4 (en) | OLIGODY DROCYTE STEM CELL PREPARATION CELLS FOR THE TREATMENT OF WHITE STROKE | |
| CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| MX2017013928A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| UY36347A (es) | Compuestos y su uso como inhibidores de bace | |
| CL2019000122A1 (es) | Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo. | |
| GT201700227A (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son utiles en el tratamiento de la enfermedad de alzheimer | |
| PL3897595T3 (pl) | Oftalmiczna kompozycja nutraceutyczna do leczenia schorzeń siatkówki z komponentą neowaskularną | |
| CL2018003013A1 (es) | Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. | |
| UY36098A (es) | Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica. | |
| PL3515409T3 (pl) | Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| ITUB20169928A1 (it) | Formulazioni farmaceutiche per il trattamento del diabete | |
| EP3461490C0 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HAEMORROID DISEASE | |
| MX2017011903A (es) | Composiciones para el tratamiento de enfermedades renales y/o hepaticas. | |
| EA201301340A1 (ru) | Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний |